Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F09%3A00208854" target="_blank" >RIV/00216208:11150/09:00208854 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)

Popis výsledku v původním jazyce

We compared the effectiveness of low doses of haloperidol and regular doses of second generation antipsychotics (SGAs) on >/=50% response measured with the Positive and Negative Syndrome Scale.and remission. In an open randomized clinical trial 498 unselected first-episode patients with schizophrenia were assigned to haloperidol, amisulpride, olanzapine, quetiapine, or ziprasidone. Within 12 months, the proportions of patients with >/=50% response were 37% for haloperidol, 67% for amisulpride, 67% for olanzapine, 46% for quetiapine, and 56% for ziprasidone. Within 12 months, the proportion of patients in remission was also the lowest in those treated with haloperidol , if compared to the patients treated with second generation antipsychotics.

Název v anglickém jazyce

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)

Popis výsledku anglicky

We compared the effectiveness of low doses of haloperidol and regular doses of second generation antipsychotics (SGAs) on >/=50% response measured with the Positive and Negative Syndrome Scale.and remission. In an open randomized clinical trial 498 unselected first-episode patients with schizophrenia were assigned to haloperidol, amisulpride, olanzapine, quetiapine, or ziprasidone. Within 12 months, the proportions of patients with >/=50% response were 37% for haloperidol, 67% for amisulpride, 67% for olanzapine, 46% for quetiapine, and 56% for ziprasidone. Within 12 months, the proportion of patients in remission was also the lowest in those treated with haloperidol , if compared to the patients treated with second generation antipsychotics.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Schizophrenia Research

ISSN

0920-9964

e-ISSN

—

Svazek periodika

115

Číslo periodika v rámci svazku

2-3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

000272423500001

EID výsledku v databázi Scopus

—